Abstract:Background: Polyphosphate (polyP), a procoagulant released from platelets, activates coagulation via the contact system and modulates cardiomyocyte viability. High-dose intravenous polyP is lethal in mice, presumably because of thrombosis. Previously, we showed that HRG (histidine-rich glycoprotein) binds polyP and attenuates its procoagulant effects. In this study, we investigated the mechanisms responsible for the lethality of intravenous polyP in mice and the impact of HRG on this process. Methods: The survival of wild-type or HRG-deficient mice given intravenous synthetic or platelet-derived polyP in doses up to 50 mg/kg or saline was compared. To determine the contribution of thrombosis, the effect of FXII (factor XII) knockdown or enoxaparin on polyP-induced fibrin deposition in the lungs was examined. To assess cardiotoxicity, the ECG was continuously monitored, the levels of troponin I and the myocardial band of creatine kinase were quantified, and the viability of a cultured murine cardiomyocyte cell line exposed to polyP in the absence or presence of HRG was determined. Results: In HRG-deficient mice, polyP was lethal at 30 mg/kg, whereas it was lethal in wild-type mice at 50 mg/kg. Although FXII knockdown or enoxaparin administration attenuated polyP-induced fibrin deposition in the lungs, neither affected mortality. PolyP induced dose-dependent ECG abnormalities, including heart block and ST-segment changes, and increased the levels of troponin and myocardial band of creatine kinase, effects that were more pronounced in HRG-deficient mice than in wild-type mice and were attenuated when HRG-deficient mice were given supplemental HRG. Consistent with its cardiotoxicity, polyP reduced the viability of cultured cardiomyocytes in a dose-dependent manner, an effect attenuated with supplemental HRG. Conclusions: High-dose intravenous polyP is cardiotoxic in mice, and HRG modulates this effect.

Effect of Polylysine on Blood Clotting, and Red Blood Cell Morphology, Aggregation and Hemolysis

Low Temperature Plasma Treatment of Rat Blood is Accompanied by Platelet Aggregation

Lysine-PEG-modified polyurethane as a fibrinolytic surface: Effect of PEG chain length on protein interactions, platelet interactions and clot lysis

Polylysine Complexes and Their Biomedical Applications

Effects of a novel low volume resuscitation solutions on coagulation and platelet function

Lysine Immobilization Through Poly(ethylene Glycol) Spacer for Bloodcompatible Polyurethane Surface

Cytotoxicity study of polyethylene glycol derivatives

Regulation Of Epithelial Cell Morphology And Functions Approaching To More In Vivo-Like By Modifying Polyethylene Glycol On Polysulfone Membranes

Investigation of the interaction between poly(ethylene glycol) and protein molecules using low field nuclear magnetic resonance.

Histidine-Rich Glycoprotein Modulates the Toxic Effects of High-Dose Polyphosphate in Mice

Evaluation of blood compatibility of MeO-PEG-poly (D,L-lactic-co-glycolic acid)-PEG-OMe triblock copolymer

Chain-length dependent effects of inorganic polyphosphate on endothelial function and nucleotide pool

In vitro hemocompatibility screening of a slippery liquid impregnated surface coating for extracorporeal organ support applications

Synthesis and evaluation of poly(hexamethylene-urethane) and PEG-poly(hexamethylene-urethane) and their cholesteryl oleyl carbonate composites for human blood biocompatibility

Antipolyphosphate monoclonal antibodies derived from autoimmune mice

Ε-Polylysine and Next-Generation Dendrigraft Poly-L-lysine: Chemistry, Activity, and Applications in Biopharmaceuticals

Influence of Interleukin-1 Beta on Platelet-Poor Plasma Clot Formation: A Potential Impact on Early Bone Healing

In vitro blood compatibility of polyacrylamide grafted polypropylene membrane

Exploring the effect of hydroxyapatite nanoparticle shape on red blood cells and blood coagulation

An Evaluation of Blood Compatibility of Silver Nanoparticles